ES2523016A1 - Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes - Google Patents

Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes Download PDF

Info

Publication number
ES2523016A1
ES2523016A1 ES201330722A ES201330722A ES2523016A1 ES 2523016 A1 ES2523016 A1 ES 2523016A1 ES 201330722 A ES201330722 A ES 201330722A ES 201330722 A ES201330722 A ES 201330722A ES 2523016 A1 ES2523016 A1 ES 2523016A1
Authority
ES
Spain
Prior art keywords
interest
cell lines
alphaviral vectors
recombinant proteins
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330722A
Other languages
English (en)
Other versions
ES2523016B1 (es
Inventor
Alejandro ARANDA
Jaione BEZUNARTEA BEZUNARTEA
Cristian Smerdou Picazo
Dámaso MOLERO SÁNCHEZ
Edita Mistiniene
Andreu SOLDEVILA FÁBREGA
Paula SERRANO PÉREZ-NIEVAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3P Biopharmaceuticals SL
Original Assignee
3P Biopharmaceuticals SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3P Biopharmaceuticals SL filed Critical 3P Biopharmaceuticals SL
Priority to ES201330722A priority Critical patent/ES2523016B1/es
Priority to US14/892,829 priority patent/US10011847B2/en
Priority to PCT/ES2014/070416 priority patent/WO2014188042A1/es
Priority to ES14801304T priority patent/ES2759916T3/es
Priority to EP14801304.8A priority patent/EP3000890B1/en
Publication of ES2523016A1 publication Critical patent/ES2523016A1/es
Application granted granted Critical
Publication of ES2523016B1 publication Critical patent/ES2523016B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes. La presente invención se relaciona con polinucleótidos y vectores alfavirales para la expresión de genes de interés en células de mamífero. Adicionalmente, la invención se relaciona con células que comprenden dichos polinucleótidos y vectores alfavirales, y que son capaces de expresar de forma estable uno o más genes de interés. La invención también se relaciona con métodos para obtener dichas células, con métodos para expresar un gen de interés en dichas células, y con métodos para reemplazar el gen de interés que dichas células expresan de forma estable por otro gen de interés.
ES201330722A 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes Expired - Fee Related ES2523016B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201330722A ES2523016B1 (es) 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
US14/892,829 US10011847B2 (en) 2013-05-20 2014-05-20 Alphaviral vectors and cell lines for producing recombinant proteins
PCT/ES2014/070416 WO2014188042A1 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
ES14801304T ES2759916T3 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP14801304.8A EP3000890B1 (en) 2013-05-20 2014-05-20 Alphaviral vectors and cell lines for producing recombinant proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330722A ES2523016B1 (es) 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes

Publications (2)

Publication Number Publication Date
ES2523016A1 true ES2523016A1 (es) 2014-11-20
ES2523016B1 ES2523016B1 (es) 2015-09-09

Family

ID=51899033

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201330722A Expired - Fee Related ES2523016B1 (es) 2013-05-20 2013-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
ES14801304T Active ES2759916T3 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14801304T Active ES2759916T3 (es) 2013-05-20 2014-05-20 Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes

Country Status (4)

Country Link
US (1) US10011847B2 (es)
EP (1) EP3000890B1 (es)
ES (2) ES2523016B1 (es)
WO (1) WO2014188042A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200283796A1 (en) * 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CN112143755A (zh) * 2020-10-19 2020-12-29 深圳市瑞普逊科技有限公司 一种人甲状旁腺激素真核表达重组质粒载体及其构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064437A2 (es) * 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
WO2012001196A2 (es) * 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
GB9326271D0 (en) 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
EP0852004B1 (en) 1995-10-11 2011-01-19 Luminex Corporation Multiplexed analysis of clinical specimens
CA2251466A1 (en) 1996-04-05 1997-10-16 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP4383530B2 (ja) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 細胞巨大分子合成の阻害が減少したアルファウイルスベクター
US6534314B1 (en) 1996-06-14 2003-03-18 Massachusetts Institute Of Technology Methods and compositions for transforming cells
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
ATE273381T1 (de) 1997-02-12 2004-08-15 Eugene Y Chan Verfahren zur analyse von polymeren
US6365731B1 (en) 1997-08-06 2002-04-02 Ambion, Inc. Stripping nucleic acids with iodine and sodium thiosulfate
KR20010031140A (ko) 1997-10-14 2001-04-16 루미넥스 코포레이션 정밀 형광염료 입자 및 그의 제조방법 그리고 그의 사용
JP4206154B2 (ja) 1997-11-13 2009-01-07 大日本住友製薬株式会社 変異型ｌｏｘＰ配列とその応用
US6451579B1 (en) 1998-07-29 2002-09-17 Invitrogen Corporation Regulated expression of recombinant proteins using RNA viruses
US6458583B1 (en) 1998-09-09 2002-10-01 Agilent Technologies, Inc. Method and apparatus for making nucleic acid arrays
US6461812B2 (en) 1998-09-09 2002-10-08 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US6436640B1 (en) 1999-03-18 2002-08-20 Exiqon A/S Use of LNA in mass spectrometry
CA2367396A1 (en) 1999-04-06 2000-10-12 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
US6465183B2 (en) 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
US6461816B1 (en) 1999-07-09 2002-10-08 Agilent Technologies, Inc. Methods for controlling cross-hybridization in analysis of nucleic acid sequences
EP1204869B1 (en) 1999-08-17 2008-10-22 Luminex Corporation Method for analyzing a number of samples from a variety of sources for a single analyte
US7122303B2 (en) 1999-09-17 2006-10-17 Agilent Technologies, Inc. Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same
US6428957B1 (en) 1999-11-08 2002-08-06 Agilent Technologies, Inc. Systems tools and methods of assaying biological materials using spatially-addressable arrays
WO2001042442A2 (en) * 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
CA2407050A1 (en) 2000-04-25 2001-11-01 Chiron Corporation Alphavirus-based vectors for persistent infection
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
AU2002334307A1 (en) 2001-09-04 2003-03-18 Exiqon A/S Novel lna compositions and uses thereof
DE10148294C1 (de) 2001-09-29 2003-01-16 Unicor Rohrsysteme Gmbh Formbackenhälfte für einen Corrugator zum Herstellen von Querrippenrohren
CA2484994C (en) 2002-04-29 2016-06-14 St. Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
ES2292271B1 (es) 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US20070243617A1 (en) 2005-10-13 2007-10-18 Holt Robert A Modular genomes for synthetic biology and metabolic engineering
GR20060100496A (el) * 2006-09-01 2008-04-15 Παρθενιος Μπουλικας ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
PL2097533T3 (pl) * 2006-11-28 2011-02-28 Proyecto De Biomedicina Cima Wektor wirusowy oraz jego zastosowania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064437A2 (es) * 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
WO2012001196A2 (es) * 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GEISS, B.J. et al., `Recombination-ready Sindbis replicon expression vectors for transgene expression¿, VIROLOGY JOURNAL, 2007, Vol. 4, Página 112, ISSN: 1743-422X (Electronic), doi: 10.1186/1743-422X-4-112, Materiales y Métodos, Figura 1. *
KARLSSON, G.B. et al., `Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors¿, METHODS MOL. BIOL., 2004, Vol. 246, Páginas 543-557, ISSN: 1064-3745 (Print), todo el documento. *
QUETGLAS, J.I. et al., `Alphavirus vectors for cancer therapy¿, VIRUS RESEARCH, 2010 Nov, Vol. 153, No. 2, Páginas 179-196, ISSN: 0168-1702, doi: 10.1016/j.virusres.2010.07.027, todo el documento. *
RIEZEBOS-BRILMAN, A. et al., `Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy¿, JOURNAL OF CLINICAL VIROLOGY, 2006, Vol. 35, No. 3, Páginas 233-243, ISSN: 1386-6532 (Print), todo el documento. *
STEEL, J.J. et al., `Infectious alphavirus production from a simple plasmid transfection+¿, VIROLOGY JOURNAL, 2011, Vol. 8, Página 356, ISSN: 1743-422X (Electronic), doi: 10.1186/1743-422X-8-356, Métodos, Figura 1. *
WANG, Y. et al., `Recombinase technology: applications and possibilities¿, Plant Cell Reports, 2011, Vol. 30, No. 3, Páginas 267-285, ISSN: 0721-7714, todo el documento. *

Also Published As

Publication number Publication date
US20160208286A1 (en) 2016-07-21
EP3000890A4 (en) 2017-02-01
EP3000890A1 (en) 2016-03-30
EP3000890B1 (en) 2019-08-14
ES2759916T3 (es) 2020-05-12
WO2014188042A1 (es) 2014-11-27
US10011847B2 (en) 2018-07-03
ES2523016B1 (es) 2015-09-09

Similar Documents

Publication Publication Date Title
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
SG10201803758XA (en) Enhanced Transgene Expression and Processing
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
MX2019002498A (es) Metodos y productos para la expresion de proteinas en celulas.
SG10201806498RA (en) Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
MX2019013498A (es) Receptor de antigeno quimerico y metodos para usarlo.
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX371025B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2016008258A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
HK1200848A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
EP2935581A4 (en) EXPRESSION VECTORS FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS
MX369109B (es) Selección novedosa de vectores y métodos de selección de células hospederas eucarióticas.
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
HK1250743A1 (zh) 表達載體組織、新的生產用細胞產生方法及其在重組產生多肽中的用途
GB201113499D0 (en) Expression of transcription factor encoding genes
ES2523016A1 (es) Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
MX2017005295A (es) Marcador de seleccion novedoso para transfeccion celular y produccion de proteinas.
MY198268A (en) Omega-hydroxylase-related fusion polypeptides with improved properties
MX2016013955A (es) Drimenol-sintasas y metodo de produccion de drimenol.
MX2016005572A (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
HK1221977A1 (zh) 用於產生供生產重組蛋白的哺乳動物生產細胞的物品和方法
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2523016

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150909

FD2A Announcement of lapse in spain

Effective date: 20211004